Chapter 32: How Peptides Are Made — Solid-Phase Synthesis, Recombinant Production, and Why Peptide Drugs Cost What They Cost

"Science is the art of the soluble." — Peter Medawar, The Art of the Soluble (1967)

Overview

Everything in this book so far has treated peptides as things that exist. This chapter is about where they come from — and it is, unexpectedly, one of the most clarifying chapters in the book, because a surprising number of arguments about peptides are settled not by biology but by manufacturing.

Consider three questions that look unrelated. Why did a 30-residue peptide that a machine can build overnight remain in shortage for two years while a company with every commercial incentive on earth tried to make more of it? Why does a vial from a research-chemical website cost a small fraction of what a pharmacy charges for what is described as the same molecule? Why does a certificate saying "98% pure" tell you considerably less than it appears to?

All three have manufacturing answers, and all three answers are learnable in an afternoon.

The chapter has an arithmetic spine. In §32.3 we will do one calculation — raising a number slightly below 1 to a power — and that single calculation explains why long peptides are hard, why purity claims are slippery, why a drug company would redesign a molecule to avoid a side reaction, and why the impurity worth worrying about in a peptide preparation is not some exotic contaminant but a molecule almost identical to the one you wanted. If you take one thing from Part VI, take the arithmetic of 99%.

Then the other route — growing peptides in living cells rather than building them atom by atom — told through the story that started the biotechnology industry: recombinant human insulin. That story has a twist most retellings miss. Getting bacteria to make insulin was the part everybody expected to be hard, and it was not the hard part.

Finally, the payoff. We will build an honest cost stack for a peptide medicine and subtract from it, piece by piece, everything a gray-market vial does not include. The conclusion is not that research chemicals are overpriced or underpriced. It is that they are a different product, and once you can name what is absent, the price difference stops being mysterious and starts being informative.

In this chapter, you will learn to:

• Explain what Merrifield actually invented and why it converted a research career into a procedure
• Walk through the Fmoc cycle conceptually and say what each protecting group is preventing
• Compute stepwise yield, and reason about what the unyielded fraction consists of
• Explain why a deletion sequence is the hardest impurity in peptide chemistry to remove
• State what "98% pure by HPLC" establishes, and what it leaves entirely open
• Explain why insulin's disulfide bonds, not its gene, were the obstacle in 1982
• Choose between synthetic and recombinant routes and defend the choice
• Name the real bottleneck behind the GLP-1 shortage and explain why money could not fix it quickly
• Decompose a peptide drug's price and locate manufacturing accurately within it

Learning Paths

This chapter is technical, and every path gets something structural from it. If you read only one section, read §32.3. If you read two, add §32.9.

💊 GLP-1 — §32.7 is the chapter for you; it answers the question that hung over Chapters 11 and 12. §32.6 explains why semaglutide cannot be made by cells alone. §32.9 explains compounded and gray-market products in one sentence. 🏋️ Performance — §32.3, §32.4, and §32.9 are, together, the most practically useful pages in Part VI. They are the manufacturing basis for everything Chapter 19 told you about the unregulated market and everything Chapter 34 will tell you about testing. 🔬 Science — read straight through. §32.1–§32.6 are the chemistry; this is the chapter Chapter 1 promised you. 💄 Cosmetic — §32.3 and §32.4 explain why cosmetic peptide ingredients are short. Short is not a limitation of imagination; it is a consequence of the arithmetic. 🏥 Clinical — §32.4 (what a purity number means), §32.7 (the shortage), and §32.8 (the cost stack) are the three sections patients ask about, and the three where confident wrong answers are most common.

32.1 Merrifield's idea: make the growing chain insoluble

Before 1963, making a peptide was a career.

The chemistry was understood. Emil Fischer had formed peptide bonds deliberately at the start of the century, and by the 1950s a determined team could assemble a small biologically active peptide — Vincent du Vigneaud's synthesis of oxytocin, nine residues, won a Nobel Prize in 1955 and took years. The difficulty was not any individual reaction. It was everything that happened between the reactions.

Here is the problem in its classical form. You want to add amino acid number four to a chain of three. You dissolve your three-residue peptide, add an excess of the next amino acid and something to activate it, and let them react. Your flask now contains the four-residue product you wanted, some unreacted starting material, a large excess of the amino acid you added, the byproducts of the activating chemistry, and whatever side products the reaction generated. Before step five, you must separate the thing you want from all of that — by crystallization, chromatography, extraction. Each purification loses material. Each takes days. And you do it again after step five, and six, and seven.

The losses compound; so does the labor. A twenty-residue peptide by this route was a heroic undertaking, and a fifty-residue peptide was essentially not available.

Robert Bruce Merrifield's insight, published in 1963, was almost embarrassingly simple to state and completely transformative in practice:

Attach the growing chain to something that will not dissolve.

That is it. Anchor the first amino acid to an insoluble bead — a resin, typically a cross-linked polymer — so that the peptide, however long it grows, stays stuck to a solid particle suspended in solvent rather than dissolved in it. Now run the same chemistry. Add your excess reagent, let it react, and then, instead of purifying, simply wash everything else away. The beads stay. Everything not attached to a bead goes down the drain.

THE MERRIFIELD SWITCH — why an insoluble anchor changes everything

  CLASSICAL SOLUTION-PHASE                 SOLID-PHASE

  peptide is dissolved                     peptide is anchored to a bead
        ↓                                        ↓
  add excess reagents                      add excess reagents
        ↓                                        ↓
  product + reagents + byproducts          product-on-bead, in a slurry with
  are all in the same solution             reagents and byproducts
        ↓                                        ↓
  SEPARATE THE PRODUCT                     FILTER AND RINSE
  (crystallize / chromatograph /           (drain the liquid, wash the beads,
   extract — days, and losses)              repeat — minutes, and near-quantitative)
        ↓                                        ↓
  next residue                             next residue

  Same chemistry. The purification step went from a research problem
  to a plumbing problem — and plumbing can be automated.

The consequence worth sitting with is not that solid-phase synthesis is faster, though it is. It is that it made the purification between steps into something a valve can do. And anything a valve can do, a machine can do. Within a decade there were automated peptide synthesizers: load the sequence, load the reagents, come back later.

Merrifield received the Nobel Prize in Chemistry in 1984, unshared, for this. The citation was essentially for turning a discipline into a technique.

It is difficult to overstate how much of this book rests on that one idea. Essentially every compound discussed in these pages exists because of it — the approved drugs and the gray-market vials alike. Semaglutide's backbone is assembled this way. So is every research peptide sold on every website you have ever been sent a link to. The same invention that made a generation of peptide medicines possible also made it possible for a small facility with a synthesizer to produce a kilogram of an unapproved compound. Chapter 1 warned you that buildability cuts both ways; this is the machine it was talking about.

🧬 The Molecule — what the "solid support" actually is

The resin is worth picturing, because "solid support" sounds like a plate and it is not.

A synthesis resin is a mass of small polymer beads, typically on the order of a tenth of a millimeter across — visible, but barely. They are usually cross-linked polystyrene or a polyethylene-glycol-based polymer, and the crucial property is that they swell. Dropped into the right solvent, a bead takes up many times its dry volume and becomes something closer to a gel than a rock.

This matters enormously. If the chemistry only happened on the outer surface of a solid sphere, the capacity would be trivial. Because the bead swells into a porous gel, the growing chains are distributed throughout its interior and reagents diffuse in to reach them. A synthesis resin is less a wall to hang things on than a sponge with chemistry happening in every pore.

The chain is joined to the resin through a deliberately chosen connector — a linker — whose job is to hold reliably through every cycle and then release cleanly at the end, so that release is a decision rather than an accident. Different linkers leave different chemical groups at the C-terminal end, which is one of several places where a manufacturing choice becomes a property of the final molecule.

Two consequences show up later in this chapter. Swelling depends on solvent and on the peptide being made — a sequence that likes to stick to itself can collapse the gel, and a collapsed gel is one reagents cannot penetrate. And the resin is consumed: loaded, used, cleaved, gone. At laboratory scale that is a footnote. At tonne scale it is a line item and a waste stream (§32.8).

32.2 The Fmoc cycle, step by step — the art of controlling which reaction happens where

Now the cycle itself. This section is conceptual, and deliberately so: it is an explanation of the chemistry, not a procedure, and it is not written to be followed. No reagent quantities, times, temperatures, or handling conditions appear here or anywhere in this book. What you need is the logic, and the logic is genuinely elegant.

Start from the central problem. An amino acid has an amino group at one end and a carboxyl at the other, and the reaction you want joins the carboxyl of one to the amino of the next. But every amino acid in the flask has both groups. Left alone, they would react in every direction at once — head to tail, tail to head, chains branching off side chains — and produce a tar of random polymers. Several amino acids also have reactive side chains: lysine has a second amino group, glutamate and aspartate have second carboxyls, cysteine has a sulfur that would happily bond to any other sulfur nearby.

So the entire art of peptide synthesis reduces to one sentence: make sure that at any given moment, exactly one pair of groups in the whole system is able to react.

That is what protecting groups do. A protecting group is a chemical cap on a reactive group that renders it inert and can be removed later under conditions leaving everything else untouched. Peptide synthesis is a game of capping everything, uncapping exactly one thing at exactly the right moment, doing one reaction, and capping again.

THE FMOC CYCLE — one residue added per pass, conceptually

  ┌─────────────────────────────────────────────────────────────┐
  │  resin bead ——[linker]—— chain ——[Fmoc]                     │
  │                                    ↑ N-terminus is capped   │
  └─────────────────────────────────────────────────────────────┘
            │
            │  1. DEPROTECT — remove the Fmoc cap from the N-terminus only.
            │     Side-chain caps are chosen to survive this. Now exactly one
            │     amino group in the system is free and reactive.
            ↓
            │  2. WASH — drain away the removal reagent and the released cap.
            ↓
            │  3. COUPLE — introduce the next amino acid, itself still wearing
            │     an Fmoc cap on ITS N-terminus and caps on any reactive side
            │     chain, with an activating reagent that makes its carboxyl
            │     group eager to react. It joins to the one free amino group.
            │     The new residue arrives already capped, so the chain cannot
            │     grow twice in one pass.
            ↓
            │  4. WASH — drain away the excess amino acid, the activator, and
            │     the byproducts. The bead retains only the chain.
            ↓
  ┌─────────────────────────────────────────────────────────────┐
  │  resin bead ——[linker]—— chain + 1 residue ——[Fmoc]         │
  └─────────────────────────────────────────────────────────────┘
            │
            └──── repeat, once per residue, N-terminus-ward ────┐
                                                                 │
  FINALLY:  5. CLEAVE — release the chain from the linker AND    │
               remove all side-chain protecting groups, generally │
               in a single step, because they were chosen to come │
               off under the same conditions.                     │
                                                                  ↓
                             crude peptide in solution → purification (§32.4)

Several features of that loop deserve comment, because each one is a design decision with downstream consequences.

The chain is built backwards relative to biology. Ribosomes build proteins N-terminus to C-terminus. Solid-phase synthesis anchors the C-terminal residue to the resin and extends toward the N-terminus, adding each new residue at the free amino end. The sequence comes out identical; the order of assembly is reversed. This is purely a consequence of which end is convenient to tie down, and it is one of the few places where a chemist's peptide and a cell's peptide differ in history but not in substance.

There are two protecting-group "levels," and they must not respond to the same trigger. The N-terminal cap comes off every cycle. The side-chain caps must survive every cycle and come off only at the end. If both responded to the same conditions the scheme would collapse. In Fmoc chemistry the N-terminal cap is removed by a mild base while the side-chain caps and the linker are removed by acid — two triggers, one used repeatedly, one used once. Merrifield's original Boc strategy inverted this, removing the N-terminal cap with a moderate acid and requiring a much harsher acid at the end. Fmoc chemistry avoids the strongest acids, which is gentler on sensitive sequences and far easier to handle at scale; it now dominates commercial manufacture, with Boc surviving for particular sequences Fmoc handles poorly.

Activation is not optional. A carboxyl group will not spontaneously attack an amino group at any useful rate, so coupling requires a reagent that converts the incoming amino acid's carboxyl into a much more reactive form. Whole families of these exist, and the differences between them — speed, hazard at scale, and how much they encourage the one side reaction chemists most fear — occupy a substantial slice of the process chemistry literature. That side reaction is racemization: the incoming residue's central carbon can flip its configuration during activation, producing a mirror-image residue. The result is a different molecule with a nearly identical mass, which should be starting to sound like a theme.

Washing is the whole point, and it is most of the volume. Steps 2 and 4 are where Merrifield's idea cashes out, and at manufacturing scale they are where an enormous fraction of the material and cost sits, because rinsing a reactor of resin thoroughly enough that no trace of the previous step survives into the next takes a great deal of solvent. Industrial peptide synthesis is largely a solvent-handling business. We return to that in §32.8, where it stops being a chemistry detail and becomes money.

Some sequences fight back. Certain stretches — often those rich in residues that hydrogen-bond with each other — cause the growing chains to associate into sheet-like aggregates on the resin. Aggregated chains are physically inaccessible: the reagents are present, the chemistry is fine, and the reaction still does not happen, because the amino group is buried. These difficult sequences are not reliably predictable from first principles. A process chemist discovers them empirically and then spends real effort designing around them. Keep this in mind for §32.3, because it is exactly where the comforting assumption of a uniform per-step efficiency breaks down.

🔍 Check Your Understanding

1. Why must the N-terminal protecting group and the side-chain protecting groups respond to different chemical triggers? What would fail if they responded to the same one?
2. The incoming amino acid arrives already carrying its own N-terminal cap. What specific error does that prevent?
3. Solid-phase synthesis extends the chain toward the N-terminus, the opposite of what a ribosome does. Does this change the final molecule? Explain your answer in terms of what a sequence is.

32.3 Why yield collapses with length — the arithmetic of 99%

This is the most important section in the chapter, and the calculation in it is the single most useful piece of arithmetic in Part VI.

Suppose your coupling chemistry is excellent. Suppose that on each cycle, 99% of the chains on the resin successfully receive the next residue. That is a very good number — it is the kind of efficiency that a well-developed process achieves — and it sounds like near-perfection.

Now ask what fraction of chains have received every residue.

Each cycle is an independent gate that 99% of chains pass. After n couplings, the fraction of chains that made it through all of them is:

0.99ⁿ

That is the whole of it. And exponentials do what exponentials do.

THE ARITHMETIC OF 99% — fraction of chains that are correct, full-length product

  couplings │  at 98%/step   at 99%/step   at 99.5%/step   at 99.9%/step
  ──────────┼──────────────────────────────────────────────────────────────
      5     │     90.4%         95.1%          97.5%           99.5%
     10     │     81.7%         90.4%          95.1%           99.0%
     20     │     66.8%         81.8%          90.5%           98.0%
     30     │     54.5%         74.0%          86.0%           97.0%
     40     │     44.6%         66.9%          81.8%           96.1%
     50     │     36.4%         60.5%          77.8%           95.1%
    100     │     13.3%         36.6%          60.6%           90.5%

  Read the 99% column across. A ten-residue peptide comes out at about 90%.
  A thirty-residue peptide — the length of GLP-1 — comes out at about 74%.
  A fifty-residue peptide comes out at about 61%.

  Now read the 50-coupling row down. Improving each step from 98% to 99%
  — one percentage point — takes the yield from 36% to 61%. Nearly double.

Work the headline numbers explicitly, because seeing them done is the point:

• 10 residues. 0.99¹⁰ = 0.904. About 90% of chains are correct.
• 30 residues. 0.99³⁰ = 0.740. About 74%.
• 50 residues. 0.99⁵⁰ = 0.605. About 61%.
• 50 residues at 98% per step. 0.98⁵⁰ = 0.364. About 36% — roughly a third.

(A pedantic and worthwhile note: a peptide of n residues requires n − 1 couplings, since the first residue is loaded onto the resin rather than coupled. The convention of counting one coupling per residue is universal in discussions like this one and makes essentially no difference to the argument, but you should know the off-by-one is there.)

Three lessons come straight off that table, and each one reorganizes something.

First: length is expensive in a way that is not linear. Doubling the length of a peptide does not double the difficulty. It squares the yield penalty. This is the deepest reason cosmetic peptide ingredients are three to eight residues long (Chapter 30), why most synthetic research compounds sit under twenty residues, and why a 191-residue growth hormone is not made chemically by anyone, anywhere, for any purpose.

Second: per-step efficiency is worth extraordinary effort. The gap between a process that couples at 98% and one that couples at 99.5% is the gap between a third of your material and three-quarters of it. This is why process chemistry — choosing activators, solvents, resins, and cycle designs — is not a detail. Getting a coupling from 99% to 99.5% on a difficult residue can be worth more than any other single improvement available.

Third, and this is the part almost everyone skips: the fraction that did not make it is not nothing. It did not evaporate. It did not fail to exist. It is still in the reactor, still attached to resin, still going through every subsequent cycle, and it will still be cleaved off at the end and end up in your crude product.

What the missing fraction actually consists of

When a coupling fails on a particular chain, that chain's N-terminus simply does not receive the new residue. But the cycle moves on. On the next cycle, the deprotection step exposes that chain's amino group again — and now it happily accepts the following residue.

The result is a chain that is missing one amino acid from the middle of an otherwise correct sequence. This is a deletion sequence, and it is the characteristic impurity of peptide synthesis.

DELETION SEQUENCES — what a failed coupling leaves behind

  target sequence, 30 residues:
      H –  A  E  G  T  F  T  S  D  V  S  S  Y  L  E  G  Q  A  A  K  E  F …  – OH
            1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21

  a chain that missed the coupling at position 9:
      H –  A  E  G  T  F  T  S  D     V  S  S  Y  L  E  G  Q  A  A  K  E  F …  – OH
            1  2  3  4  5  6  7  8  ✗  9 10 11 12 13 14 15 16 17 18 19 20

  What you now have in the vessel:
    · 29 residues instead of 30
    · the same N-terminus and the same C-terminus
    · the same charge, near enough
    · the same hydrophobicity, near enough
    · the same behavior on a chromatography column, VERY near enough
    · a mass difference equal to one residue: 57 Da if it was a glycine,
      71 Da if alanine, 113 Da if leucine — out of a total of ~3,400 Da

  This is not a contaminant that stands out. It is a near-twin.

Now compare that to the impurities you might have expected to worry about. A solvent residue, a metal, a bacterial endotoxin — these are chemically unlike a peptide, and separating them from a peptide is straightforward. A deletion sequence is a peptide, made of the same amino acids in nearly the same order, differing by one residue in perhaps thirty. It elutes from a chromatography column at nearly the same time. It carries nearly the same charge. Under many analytical conditions it hides directly underneath the main peak.

This is the chapter's link forward to Chapter 34 and backward to Chapter 19. When Chapter 19 described unregulated peptide products of uncertain composition, the composition problem it was describing is largely this one. And when Chapter 34 explains why mass spectrometry rather than HPLC alone is required to characterize a peptide, the reason is sitting in the diagram above: HPLC separates by physical behavior, and a deletion sequence behaves almost identically. Mass spectrometry can see a 57-dalton difference. A retention time frequently cannot.

Chemists have a partial answer, and it is worth knowing because it illustrates how process design works. After each coupling, a manufacturer can deliberately cap any chain whose coupling failed — permanently blocking its N-terminus so it can never receive another residue. That chain is now dead. It stops at whatever length it had reached, becoming a truncated sequence rather than a deletion sequence. Truncated chains are shorter, more different, and therefore far easier to separate. Capping does not improve yield at all — it converts an unyielded chain from a hard problem into an easy one. That trade is often worth making, and the decision of whether to cap is a real one that process chemists argue about.

The link back to Chapter 4 and semaglutide

Chapter 4 §4.5 mentioned, in passing, that semaglutide carries a substitution at position 34 — a lysine replaced by an arginine — and noted that this exists to prevent a related problem. This section is where that becomes concrete.

Semaglutide's long duration of action comes from a fatty acid chain attached to the side chain of a lysine. Chapter 1 §1.2 told you why: lysine's side chain ends in a free amino group, the standard chemical handle. Now suppose the molecule contained two lysines. The attachment chemistry cannot tell them apart. Some molecules would be modified at one, some at the other, some at both — producing a mixture of attachment isomers: identical composition, identical mass, differing only in where the fatty acid ended up.

That is a manufacturing nightmare. Identical mass means mass spectrometry cannot distinguish them; near-identical physical properties mean chromatography struggles. And they are not pharmacologically equivalent, because where the fatty acid attaches determines how the molecule folds against albumin and presents to its receptor.

The solution was structural rather than analytical: change one lysine to an arginine. Arginine is also positively charged, so the molecule's character is preserved, but its side chain does not offer the same handle. Now there is exactly one attachment site, and the ambiguity is designed out of existence rather than purified out afterwards.

That is what manufacturing-aware molecular design looks like, and it is the answer to anyone who describes analog design as arbitrary tinkering. A residue was changed for a reason with nothing to do with receptor biology and everything to do with a factory having to make one molecule and not two.

📊 Evidence Rating

Claim: Solid-phase peptide synthesis, as introduced by Merrifield in 1963, is the enabling technology for the modern peptide field — both the approved drugs and the unregulated market. Rating: ✅ Strong evidence (historical and technical claim; assessed as of 2026) Why: This is a settled matter of scientific and industrial record rather than a contested empirical claim. The method was recognized with an unshared Nobel Prize in Chemistry in 1984, it is the documented basis of commercial manufacture for the great majority of synthetic peptide drug substances, and no competing account of the field's development exists. What would change it: Nothing plausible. The only way this rating moves is if the historical record were shown to be wrong about who published what, which is not a live possibility.

🔍 Check Your Understanding

1. A process couples at 99% per step. What fraction of chains are correct full-length product for a 12-residue peptide? For a 40-residue peptide? Show the calculation.
2. Why is a deletion sequence harder to remove than a residual solvent?
3. Capping does not increase yield. Explain, in one sentence, why a manufacturer would do it anyway.
4. Semaglutide's position-34 substitution prevents a mixture of attachment isomers. Why would that mixture be especially difficult to detect?

32.4 Purification, and what "98% pure" leaves behind

The reactor has now been cleaved. What comes off the resin is a crude peptide — the product you wanted, plus deletion sequences, plus truncated sequences, plus whatever fraction racemized, plus the chemical debris of the cleavage step itself.

Purification is where this becomes a drug substance, and the workhorse is preparative high-performance liquid chromatography — preparative HPLC. The principle is the analytical HPLC of Chapter 34, run at a scale where the goal is collecting material rather than measuring it: the mixture is pushed through a packed column under pressure, molecules travel at different speeds according to their chemical character, and fractions are collected across the peak of interest. Remove the solvent — usually by freeze-drying, or lyophilization — and you have a powder.

Preparative HPLC is effective, well understood, and expensive. It consumes large volumes of solvent and expensive column packing, it takes time, and — importantly — it always throws something away. Every purification trades purity against recovery: cut the collection window narrowly for very pure material at low yield, or widely for more material that is less pure. That trade is a business decision made against a specification, and it is one of the first places where pharmaceutical and research-grade material genuinely diverge.

What a purity number actually says

Now the part that matters for anyone reading a certificate of analysis.

A statement like "98% pure by HPLC" is a statement about the output of one specific analytical method, and the crucial questions are pure by what measure and with respect to what.

The usual measure is area percent: the detector traces a signal, peaks are integrated, and the peak assigned to the product is reported as a percentage of total integrated peak area. That is a real, reproducible, useful number, and it is narrower than most people assume.

It does not establish identity. Area percent says one peak accounts for 98% of the detected signal. It does not say that peak is the molecule on the label — a well-purified preparation of entirely the wrong peptide gives a beautiful purity figure. Identity requires a different measurement, which is why Chapter 34 treats it as a separate question.

It does not see what does not absorb. Detection is usually by ultraviolet absorbance at a wavelength where the peptide bond and aromatic side chains absorb. Anything that absorbs weakly or not at all contributes little or no peak area regardless of how much is present. Salts are invisible.

It does not resolve what co-elutes. This is the §32.3 problem arriving in the analysis. If a deletion sequence comes off the column at the same time as the product, the integration software sees one peak and calls it one thing. It is not lying; it cannot see the difference. This is why a purity method must be shown to separate the impurities a specific process is known to generate, and why a purity number from an unnamed method is close to uninterpretable.

And it says nothing about mass balance. Which is the big one.

Purity and content are two different numbers

Here is a fact that surprises nearly everyone the first time they meet it: a vial of peptide that is genuinely 98% pure by HPLC may contain substantially less than 98% peptide by mass.

Those are not contradictory statements, because they measure different things. Purity is a ratio among the peptide species present. Peptide content is the fraction of the vial's total mass that is peptide at all. The rest is made of things the purity assay was never asked about:

Counterion. Peptides with basic residues come out of purification as salts, and in the most common purification chemistry the counterion is trifluoroacetate — TFA — because trifluoroacetic acid is used both in cleavage from the resin and as an HPLC mobile-phase additive. Every positively charged group on the peptide pairs with one, so a peptide with several arginines and lysines carries a lot of counterion mass. This is why pharmaceutical processes often include a deliberate salt-exchange step, and why "TFA salt" versus "acetate salt" on a label is a real distinction rather than pedantry.

Water. Lyophilized peptides are hygroscopic. A freeze-dried powder holds residual water from the process and takes up more from the air whenever the vial is opened. Not a defect; a property.

Residual solvent and process reagents. Small amounts of what the process used.

Depending on how many basic residues a peptide has and how it was dried, the combined counterion and water fraction of a lyophilized powder is routinely in the double digits as a percentage of total mass. Which means the arithmetic everyone does intuitively — the label says 10 milligrams, so there are 10 milligrams of peptide — is not reliable, and the gap is not small.

This is why pharmaceutical specifications state peptide content as its own parameter, determined by methods that measure peptide mass directly — amino acid analysis, quantitative NMR against a certified standard — rather than inferring it from a chromatogram. It is also why the mass on a research-chemical label is best understood as a statement about what was weighed into the vial, which is a different claim from how much peptide is in it.

WHAT IS ACTUALLY IN THE VIAL — purity and content are different questions

  A vial reported as "98% purity by HPLC", schematically:

  ┌────────────────────────────────────────────────────────────┐
  │ TOTAL MASS IN VIAL                                         │
  │                                                            │
  │  ┌──────────────────────────────────┐ ┌──────┐ ┌────────┐ │
  │  │  PEPTIDE                         │ │ TFA  │ │ WATER  │ │
  │  │  ┌────────────────────────────┐  │ │counter│ │        │ │
  │  │  │ target peptide      ~98%   │  │ │ ion  │ │        │ │
  │  │  ├────────────────────────────┤  │ │      │ │        │ │
  │  │  │ deletions, etc.      ~2%   │  │ │      │ │        │ │
  │  │  └────────────────────────────┘  │ └──────┘ └────────┘ │
  │  │   ↑ THIS ratio is the 98%        │  ↑ these do not     │
  │  │     "purity by HPLC"             │    appear in it     │
  │  └──────────────────────────────────┘                     │
  └────────────────────────────────────────────────────────────┘

  Purity = target ÷ (all peptide species detected)
  Content = peptide mass ÷ total mass in the vial

  Both can be true. Neither implies the other. And a certificate that
  reports only the first has not answered the second.

Beyond both sit questions no purity assay addresses at all: sterility, bacterial endotoxin, particulate matter, and stability over a stated shelf life. A chemically pure peptide is not a sterile peptide, and nothing about a chromatogram speaks to what the powder will look like in eight months in a warm room. Chapter 34 is the full treatment of testing; this is the manufacturing origin of why those tests are separate.

📊 Evidence Rating

Claim: A certificate stating "98% purity by HPLC" establishes that the vial contains 98% of the labeled peptide by mass. Rating: ❌ Hype outpaces evidence (assessed 2026) Why: Purity by peak area and peptide content are different quantities measuring different things. Area percent is a ratio among UV-detected peptide species; it excludes counterion, water, and non-absorbing residues entirely, and those can together be a double-digit percentage of the powder's mass. The certificate is not necessarily false — it is answering a different question from the one the reader is asking. What would change it: A certificate that additionally reports peptide content by a method that measures peptide mass directly — amino acid analysis, quantitative NMR against a certified reference, or equivalent — together with counterion identity and water content, and that names the HPLC method and shows it resolves the known process impurities. That combination would support the mass claim. It is exactly what a pharmacopeial specification requires, and exactly what is generally absent from research-chemical documentation.

⚠️ Hype Check — "pharmaceutical grade"

The claim, in its usual form:

"Our peptides are pharmaceutical grade, 99%+ purity, manufactured in an ISO-certified facility."

What's true in it. Some of the underlying facts may be entirely real. The synthesis may be competent, the purity figure accurate as far as it goes, the certifications genuine. Assuming fraud is the wrong instinct.

Where it fails. "Pharmaceutical grade," applied to a research chemical, is not a defined regulatory term. No authority inspects a product and confers that designation. Anyone may print it on anything. It borrows the credibility of a regulated category while committing to nothing checkable.

Contrast it with a real quality claim: manufactured under GMP — Good Manufacturing Practice — to a specified pharmacopeial monograph**, meaning a published public standard (a USP or Ph. Eur. monograph) listing the required tests, methods, and limits for identity, purity, individual and total impurities, water, residual solvents, counterion, and where applicable sterility and endotoxin. That claim names a document you can go read and implies a facility subject to inspection against a defined standard.

Notice the difference in kind. "Pharmaceutical grade" is an adjective. "Manufactured under GMP to monograph X, with batch release testing against it" is a claim with a referent. The second is the sort of thing that can be wrong. The first cannot be wrong, because it does not say anything.

Verdict: treat "pharmaceutical grade" on a research-chemical product as a marketing term carrying no information. The useful follow-up is simply: to what monograph, under what standard, tested by whom?

📊 Evidence Rating

Claim: "Pharmaceutical grade," as applied to a research-chemical peptide product, is a meaningful quality designation. Rating: ❌ Hype outpaces evidence (assessed 2026) Why: It is not a defined regulatory term in that context and there is no body that confers it. The defined, checkable alternative — manufacture under GMP to a named pharmacopeial monograph, with batch release testing against that monograph — is a specific claim that products using the phrase generally do not make. What would change it: A jurisdiction defining and enforcing the term, or — far more likely and more useful — a seller replacing it with the specific claim: named monograph, named standard, named testing laboratory, batch-specific certificate. That is not a rating change so much as the claim being replaced by a better one.

32.5 Recombinant production: insulin as the case study

The other route does not build peptides. It grows them.

Recombinant production means inserting the gene for the peptide you want into a host organism, growing that organism at scale, and harvesting what it makes. Peptide bond formation is handled by the host's own ribosomes, at a rate and accuracy no synthesizer approaches. The host is typically a bacterium — Escherichia coli — or a yeast, and for some products a mammalian cell line.

The economics are entirely different. Where solid-phase synthesis pays per residue in reagent, solvent, and cycle time, fermentation pays for infrastructure and then produces long chains about as easily as short ones. A ribosome adding residue 150 costs what residue 3 cost. The exponential from §32.3 does not apply, because cells proofread and because a cell that makes a defective chain generally degrades it rather than shipping it.

The story that established all of this is recombinant human insulin, and the popular version puts the difficulty in the wrong place.

1982: the first approved recombinant drug

Before 1982, therapeutic insulin came from the pancreases of slaughtered cattle and pigs. It worked — it had kept people alive since 1922 (Chapter 11) — but animal insulin differs from human insulin in sequence, so a meaningful minority of patients mounted immune responses to it; supply was tied to meat production, an uncomfortable dependency for a drug people die without; and purification from animal tissue was never going to be elegant.

The recombinant route was demonstrated in the late 1970s, in work published in 1979 by a group at Genentech with the City of Hope, and reached approval in 1982 as the first recombinant DNA drug approved anywhere. The biotechnology industry as a commercial category dates from that approval.

What was hard about it? Not the part everyone assumes. Getting a bacterium to express a human gene was, by the standards of the moment, the tractable half: insulin's chains are short, the genes could be chemically synthesized outright rather than isolated from tissue, and expression in E. coli was demonstrable.

The hard part was folding.

WHY INSULIN IS NOT JUST A SEQUENCE

  Insulin is TWO chains held together by disulfide bonds:

      A chain (21 residues)   ——S——S——   ┐
             │                            ├─ two INTERCHAIN bridges
             └──S──S──  (one INTRACHAIN bridge within the A chain)
                                          │
      B chain (30 residues)   ——S——S——   ┘

  Six cysteines. Three specific pairings out of the fifteen pairings
  that six cysteines could form. Get the pairing wrong and you have a
  molecule of identical composition, identical mass, and no activity.

  A ribosome can make the chains. Nothing about making the chains
  guarantees the bridges form in the right places.

Chapter 1 §1.2 called the disulfide bond biology's staple. Insulin is held together by three of them, and their placement is not optional — it is the tertiary structure, and the tertiary structure is what the receptor recognizes. Six cysteines can pair in fifteen ways. One is right.

A human beta cell solves this elegantly: insulin is not made as two chains. It is made as a single chain — proinsulin — in which the future A and B chains are joined by a linking segment, the C-peptide. The single chain folds as one piece, bringing the correct cysteines into proximity and making the correct pairing overwhelmingly favored. Only after folding is the connecting segment cut out enzymatically. The linker's entire job is to make folding easy, and then to leave.

The early recombinant approach did not use that trick. It expressed the A and B chains separately, purified each, and then combined them and coaxed the disulfides to form. This works — it produced a drug that reached patients — but chain combination is inherently inefficient, because two chains in solution have no particular reason to find each other in the right register before doing something less useful.

Later processes adopted biology's own answer: express a single-chain precursor, let it fold as one piece, then cleave it enzymatically. Manufacturers took different routes to that — bacterial systems producing a precursor recovered from inclusion bodies (dense aggregates of misfolded protein that E. coli forms when overexpressing a foreign protein) and then refolded; yeast systems secreting a precursor already correctly folded, avoiding refolding at the cost of other complexities.

The lesson generalizes far beyond insulin: in recombinant production, expression is often the easy half and folding is the hard half. Getting a cell to make a chain is molecular biology. Getting that chain into the one conformation that works, reproducibly, batch after batch, is protein chemistry and process engineering — and that is where the effort goes.

🔬 Read the Study

Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD. "Expression in Escherichia coli of chemically synthesized human insulin genes." Proceedings of the National Academy of Sciences USA, 1979.

What they did. Chemically synthesized genes encoding the human insulin A and B chains separately, inserted each into E. coli as a fusion with a bacterial protein, and showed that the bacteria expressed the corresponding chains. The chains were then released from their fusion partners, purified, and combined to form insulin with the correct disulfide bonds.

What it established. That a human peptide hormone could be produced by a bacterium from a synthetic gene, and that the material could be assembled into the authentic active molecule. That is the technical foundation of the biotechnology industry.

What to notice in how it was done. First, the fusion strategy. Neither chain was expressed alone; each was joined to a bacterial protein. This is a recurring device — a small foreign peptide expressed by itself is often degraded by the host or made in useless quantity, and attaching it to something the cell makes happily gets around that. The fusion partner then has to be removed, which means the process needs a cleavage step that cuts in exactly one place. That constraint shapes what sequences the strategy suits.

Second, the disulfides were formed after the fact, by combining separately produced chains. The paper's achievement is expression; the combination step is where the yield problem lived, and it is why later industrial processes moved to single-chain precursors that fold before they are cut. A good illustration of a general truth: the first demonstration of a route and the eventual industrial version are often quite different processes, and the difference is usually yield rather than feasibility.

What it does not tell you. Nothing about the process any current insulin product uses, which has moved on considerably. Nothing about formulation, where insulin analogs get their distinct time courses (Chapter 11). And nothing about pricing, which is Chapter 12's subject and has essentially no relationship to this paper.

💊 In the Clinic — what is actually in an insulin vial

Animal-sourced insulin is no longer the standard of care anywhere with a functioning supply chain. What a pharmacy dispenses is either recombinant human insulin — the identical human sequence, produced in bacteria or yeast — or a recombinant analog, whose sequence has been deliberately altered to change how quickly the molecule disperses from an injection site.

Those analogs are why "rapid-acting" and "long-acting" insulins exist, and the mechanism is the quaternary structure Chapter 1 §1.4 mentioned. Insulin stores as a zinc-coordinated hexamer and must dissociate into single molecules to act. Destabilize the hexamer and it disperses faster; make the molecule precipitate at tissue pH or bind albumin and it disperses slower. Same receptor, same biology, different physics of getting there.

Two things patients ask that this chapter answers. Why refrigeration? Because it is a folded peptide in aqueous solution, and heat, agitation, and time all push folded peptides toward aggregation — a loss of potency and a potential immunogenicity concern. Why isn't there a generic? Because insulins are regulated as biologics rather than small-molecule generics, so a competitor must demonstrate biosimilarity through its own program rather than simply matching a chemical structure. That is a regulatory and manufacturing answer to what people assume is a purely commercial question — though Chapter 12 is clear that commercial factors are very much present too.

None of this is a basis for changing how anyone uses a prescribed medicine. That conversation belongs with a clinician.

32.6 Choosing between them

So: build it or grow it?

The choice is not ideological, and it is usually not close once you know the molecule. Four factors decide it.

Length. This is the dominant term, and §32.3 is why. Below roughly twenty residues, synthesis is straightforward. In the thirty-to-fifty range it is demanding but entirely industrial — this is where GLP-1 analogs live. Beyond that, the exponential becomes punishing and recombinant production takes over. Growth hormone at 191 residues is recombinant, universally. A 9-residue peptide like oxytocin is synthetic, universally. Semaglutide, at 31 residues with substantial chemical modification, sits in between and uses both kinds of step.

Non-natural components. A ribosome can only install the twenty amino acids the genetic code specifies. If a molecule contains anything else, the ribosome cannot make it, full stop. This is not a preference or an efficiency argument; it is a hard constraint, and it decides the question by itself.

Semaglutide is the clean example. Its position-8 residue is Aib — α-aminoisobutyric acid — which is not one of the twenty and is not encoded by any codon. Chapter 4 explained why it is there: Aib's structure blocks the enzyme DPP-4 from cleaving the molecule, which is a large part of why semaglutide lasts as long as it does. No cell can make that residue into a peptide chain by ribosomal synthesis. Semaglutide therefore requires chemical steps, regardless of any other consideration.

Site-specific chemical modification. The same argument extends past the backbone. Semaglutide's fatty acid chain, attached through a defined linker to one specific lysine, is chemistry. Cells do perform their own post-translational modifications — glycosylation especially — but according to their own biology rather than a chemist's design, and they do not attach synthetic fatty diacids through engineered spacers. Wherever a molecule carries a deliberate, precisely placed chemical group, a chemical step is involved.

Folding complexity. This cuts the other way. If the molecule has multiple disulfide bonds that must form in a specific pattern, cells are dramatically better at it than flasks — the whole lesson of §32.5. One disulfide can be handled synthetically without much drama. Several is a folding problem, and folding problems want a cell.

CHOOSING A ROUTE — a decision sketch

  Does the molecule contain a non-natural residue,
  a D-amino acid, or a designed chemical modification?
        │
        ├── YES ──→ CHEMICAL STEPS ARE REQUIRED. The only question is
        │           whether the backbone is synthesized or expressed.
        │           (semaglutide, tirzepatide: hybrid — see below)
        │
        └── NO
             │
             How long is it?
             │
             ├── under ~20 residues ────→ SYNTHESIS
             │                            (oxytocin, octreotide, cosmetic peptides)
             │
             ├── ~20–50 residues ───────→ EITHER. Decided by folding needs,
             │                            volume, and existing plant.
             │
             └── over ~50 residues ─────→ RECOMBINANT
                                          (insulin, growth hormone, erythropoietin)

  Cutting across all of it: complex disulfide pattern → strongly favors recombinant.
                            very large annual volume  → favors recombinant.
                            precise chemical decoration → requires chemistry.

Many modern products are hybrids, and this is the point most summaries miss. The routes are not rivals; they are stages. A backbone can be produced recombinantly — cheaply, at length, correctly folded — and then chemically modified in a defined step afterwards. Or a backbone can be synthesized in fragments and joined. Or a synthetic backbone can be decorated chemically. What a real manufacturing process looks like is a sequence of steps chosen for each part of the molecule, not an allegiance to a method.

Two techniques worth naming because they blur the boundary further. Fragment condensation builds a long peptide by synthesizing several shorter pieces separately, purifying each, and then joining them — which is a direct assault on the §32.3 exponential, because three purified 15-residue fragments joined into a 45-residue chain suffer nothing like the yield collapse of 45 sequential couplings. Native chemical ligation, introduced in the mid-1990s, allows two unprotected peptide fragments to be joined selectively in water at a specific junction, which extended the practical reach of chemical synthesis into territory that had previously been recombinant-only. Both exist because the arithmetic in §32.3 is a real constraint that chemists have spent thirty years engineering around.

🔍 Check Your Understanding

1. A peptide is 34 residues long, contains only standard amino acids, and has no disulfide bonds. Which route would you expect, and what additional information would change your answer?
2. Why can no purely recombinant process produce semaglutide? Give the specific structural reason.
3. Growth hormone is 191 residues and is produced recombinantly. Using the table in §32.3, estimate what fraction of chains would be correct full-length product if it were synthesized at 99% per coupling. Comment on your answer.

32.7 Manufacturing at GLP-1 scale — the constraint behind the shortage

This book has referred repeatedly to the GLP-1 shortage — Chapter 11 in passing, Chapter 12 at length, Chapter 19 as the reason a compounding industry appeared. This section explains it.

For roughly two years, demand for semaglutide and tirzepatide exceeded supply. Both appeared on regulatory shortage lists. Prescriptions went unfilled, patients were switched between products and dose strengths on the basis of availability rather than clinical indication, and a secondary market in compounded and unapproved alternatives grew into the gap — a market that existed lawfully in some jurisdictions precisely because a shortage was formally declared, and that largely lost that footing when the shortages were resolved, tirzepatide first and semaglutide after it.

The obvious hypothesis is that the peptide was hard to make, and given §32.3 that is a reasonable guess: a 31-residue peptide with a non-natural residue and a chemically attached fatty acid chain is not trivial.

The obvious hypothesis was wrong. Synthesis capacity was expanded, aggressively and successfully. Drug substance was not what ran out.

The binding constraint was aseptic fill-finish and injector-pen assembly — the final steps, after the molecule already exists.

What fill-finish actually is

Every injectable medicine must end up inside a sterile container, in the right volume, at the right concentration, with nothing living in it. That final operation is fill-finish, and when it cannot include a terminal sterilization step — the case for peptides, because the heat or radiation that would sterilize a sealed vial would also damage the molecule — it must be done aseptically: every component sterilized separately, then combined in an environment engineered so contamination cannot enter.

THE STEPS AFTER THE MOLECULE EXISTS

  drug substance (the purified peptide)
        ↓
  FORMULATION — dissolve in a buffer, add stabilizers and tonicity agents
                and preservative where required; control aggregation
        ↓
  STERILE FILTRATION — the solution is filtered to remove microorganisms;
                       the filter itself is validated and tested
        ↓
  ASEPTIC FILL — the sterile solution is dispensed into sterilized
                 cartridges or vials in a controlled environment, with
                 continuous environmental monitoring, by operators who
                 cannot touch anything, or by isolators and robotics
        ↓
  DEVICE ASSEMBLY — for a pen: the cartridge is built into a device with
                    a dose-setting mechanism, a spring, a plunger and a
                    housing, assembled to tolerances that must hold across
                    hundreds of millions of units
        ↓
  INSPECTION, LABELING, PACKAGING, RELEASE TESTING
        ↓
  COLD CHAIN — refrigerated storage and distribution to the pharmacy

  Every one of these steps is regulated. Every one is a potential bottleneck.
  Only the first is chemistry.

Two properties of that chain made it the constraint.

It is capital-intensive and slow to build. A sterile fill line is not equipment you order and plug in. It is a facility: clean rooms with classified air handling, isolators or barrier systems, water-for-injection systems, environmental monitoring, gowning and training regimes, and validation. Validation is the part people underestimate. Before a line may make product for patients it must be qualified — demonstrated, documented, inspected — including media fill runs in which the line produces thousands of units of growth medium instead of drug to prove nothing contaminates them. A sterile fill line takes years to build and qualify. Not months.

The device is its own manufacturing problem. A prefilled injector pen is a precision mechanical product made to medical-device standards, and at these volumes it is one of the larger precision-assembly undertakings in the industry — tooling, automated lines, and their own qualification, with the added constraint that a device failure in the field is a patient-safety event.

Put those together and the shortage stops being mysterious. You cannot buy your way out of a constraint whose limiting factor is time. The commercial incentive was as large as any in the modern pharmaceutical industry and still did not produce capacity quickly, because the capacity in question is a regulated physical plant whose qualification timeline money shortens only at the margins. The responses available were the ones that timeline permits: acquiring existing qualified fill sites rather than building new ones — one manufacturer bought a major contract manufacturer's sites for precisely this reason — contracting external capacity wherever it existed, and prioritizing which products and dose strengths got the lines they had.

Remember this section whenever someone explains a drug shortage in terms of the active ingredient. Sometimes that is right. For GLP-1 receptor agonists it was not, and the mistake led many people to conclude that anyone with a synthesizer could solve the problem — precisely the reasoning error whose consequences Chapter 19 documents and which §32.9 dismantles.

💊 In the Clinic — what the shortage looked like from the patient side

The manufacturing story above had clinical consequences worth naming, because they explain behavior that otherwise looks irrational.

Shortages of injector-pen products are frequently dose-strength-specific, because different strengths run on different lines or configurations. A patient could find one strength available and the adjacent one absent — which sounds like rationing but is a consequence of how fill lines are scheduled.

Interruptions matter clinically for GLP-1 receptor agonists in a way they do not for every drug, because these medicines are titrated upward slowly to manage gastrointestinal side effects (Chapter 8). Someone who stops for six weeks and restarts at their previous dose may have lost tolerance to it. Restarting is a clinical decision, not an assumption.

The shortage also created the conditions for the compounded-product market, because in the United States compounding of what is otherwise a copy of a marketed product is permitted while that product is formally listed in shortage. When the listings resolved, that permission ended — which is why many patients experienced a sudden change in availability that had nothing to do with anything clinical.

None of this is guidance. If a supply interruption affects a medicine you take, that decision belongs with the clinician who prescribed it, and Chapter 39 is about making that conversation productive.

32.8 The honest cost stack

Now we can build the price of a peptide medicine honestly, which means both refusing to pretend manufacturing is trivial and refusing to pretend it explains the number on the invoice.

WHAT GOES INTO THE PRICE OF A PEPTIDE MEDICINE

  ── MAKING THE MOLECULE ────────────────────────────────────────────
   1. SYNTHESIS or FERMENTATION
      reagents, solvents (in very large volumes), resin, amino acid
      building blocks, energy, reactor time, operator time
   2. PURIFICATION
      preparative HPLC: columns, packing, solvent, and the material
      discarded in every purification trade-off
   3. DRYING / ISOLATION and salt exchange

  ── MAKING IT A MEDICINE ───────────────────────────────────────────
   4. FORMULATION
      buffers, stabilizers, tonicity agents, preservatives; the
      science of keeping a peptide from aggregating for two years
   5. ASEPTIC FILL-FINISH
      sterile facility, validation, environmental monitoring, and
      the yield lost to inspection rejects
   6. DELIVERY DEVICE
      pen or autoinjector: components, precision assembly, device
      regulatory compliance
   7. COLD CHAIN
      refrigerated warehousing and validated shipping, everywhere,
      continuously, with monitoring

  ── PROVING IT IS A MEDICINE ───────────────────────────────────────
   8. QUALITY CONTROL AND RELEASE TESTING
      identity, purity, impurity profile, potency, content, water,
      residual solvent, sterility, endotoxin, particulates, stability
   9. QUALITY SYSTEMS AND REGULATORY COMPLIANCE
      documentation, deviation management, audits, inspections,
      pharmacovigilance, ongoing stability programs

  ── EVERYTHING THAT CAME BEFORE ────────────────────────────────────
  10. RECOVERED DEVELOPMENT COST
      the clinical program for THIS drug, plus an allocated share of
      the programs that failed — which is most of them
  11. MARKET STRUCTURE
      patents and exclusivity, negotiated rebates, intermediaries,
      payer mix, and what different national systems will pay

  Blocks 1–3 are the part people mean by "manufacturing cost."
  Blocks 1–9 are the part that is genuinely cost.
  Blocks 10–11 are where the price mostly lives.

Two things must both be said, and people usually manage only one of them.

The first block is genuinely substantial, and dismissing it is wrong. There is a persistent claim that peptide drugs cost "pennies to make." That is not accurate for a finished, sterile, tested, device-delivered pharmaceutical. Industrial peptide synthesis consumes solvent at a scale that surprises people who have only seen it in a laboratory — high enough that it is a recognized environmental problem and an active area of process-chemistry research, which is not the profile of a trivial cost. Preparative HPLC at manufacturing scale is expensive equipment consuming expensive consumables and discarding material by design. Aseptic fill-finish carries the fixed cost of a validated sterile facility. Quality control is a long list of individually non-trivial assays, run on every batch. None of that is pennies.

And the first block does not explain the price. The decisive observation is empirical rather than theoretical: the same product, from the same manufacturer, made in the same facility, sells at radically different prices in different countries. The manufacturing cost of a pen sold in one national market and the identical pen sold in another is, to a very good approximation, identical. The prices are not. No cost-of-goods account explains a difference that large between two units that came off the same line.

Chapters 11 and 12 covered where the difference comes from: patent and exclusivity protection, the structure of pharmaceutical purchasing in each country, negotiated versus administered pricing, intermediaries, and — legitimately — recovery of development costs including the large majority of programs that fail before approval. That last item is a real cost of the industry existing, and an honest account includes it. But it is a cost of development and market structure, not of manufacture, and conflating the two produces confident wrong answers in both directions.

📊 Evidence Rating

Claim: The price of peptide drugs is explained by their manufacturing cost. Rating: ❌ Hype outpaces evidence (assessed 2026) Why: Manufacturing cost is real and non-trivial — synthesis, purification, aseptic fill-finish, devices, cold chain, and batch release testing are all substantial — but it cannot account for the observed facts. The same product, from the same manufacturer and often the same facility, sells at multiples of difference across national markets, and no cost-of-goods account explains a difference between identical units. Price is set predominantly by exclusivity, market structure, and payer negotiation, together with recovery of development costs including failed programs (Chapters 11, 12). What would change it: Evidence that international price differences track differences in manufacturing or distribution cost rather than differences in market structure; or a market in which exclusivity has expired and prices converge toward cost, which is the natural experiment that loss of exclusivity will eventually run. Note the direction of that second test: it would refine the rating rather than reverse it, by showing what the cost floor actually is.

32.9 Why a research vial is cheap and a prescription is not

Everything in this chapter converges here.

Someone comparing a pharmacy price to a research-chemical website price sees two numbers and naturally concludes that one is inflated. That framing carries an unexamined assumption: that the two numbers are prices for the same thing. They are not, and this chapter has now enumerated how they differ.

A gray-market vial's price reflects synthesis and basic purification and essentially nothing else. Walk down the cost stack from §32.8 and cross out what is absent:

• Formulation science — absent. There is a peptide powder, not a solution engineered to keep that peptide stable, monomeric, and potent for a defined shelf life.
• Aseptic fill-finish — absent. This is the single largest omission. A vial filled outside a qualified sterile process is not a sterile product, whatever it says on the label, and Chapter 19 documented that this is where actual documented harm in this market has come from.
• A delivery device — absent.
• Cold chain — absent, or at best unverified. What happened to that vial between the facility and the courier and the doorstep is not recorded and generally not recoverable.
• A quality control system — absent. Not necessarily testing — a certificate may exist — but the system: defined specifications, validated methods, batch records, retained samples, stability programs, deviation investigations, and someone whose job and license depend on the release decision.
• Regulatory compliance — absent, by construction. The product is sold under a label that disclaims human use precisely so that none of this applies.
• Clinical evidence — absent. Nothing in the price paid for a trial, because there was no trial (Chapter 19).
• Liability — absent, and this one is worth pausing on. There is no party who has accepted responsibility for what is in the vial. The disclaimer is not decorative; it is the entire legal structure of the transaction.

It is cheaper because it is a different product, not because someone found efficiencies.

That sentence is the most useful one in this chapter. Read it neutrally: it is not a moral claim and not an argument that the pharmacy price is justified — Chapter 12 is genuinely critical of drug pricing and this chapter retracts none of it. It is a claim about what a price difference is evidence of.

If a research vial were the same product made more efficiently, the gap would be evidence of market failure and nothing more. Instead the gap is largely a measure of what has been removed. Every item on the list above costs money, and every item is something an identifiable party does so that the person injecting the material does not have to hope.

Two corollaries that people consistently get backwards.

A price gap of that size is not evidence that the molecule is easy to make. §32.3 and §32.7 both say otherwise. The gap is evidence about which stages were performed, not about how hard the first stage is.

And a certificate of analysis does not close it. This is the most common counterargument, and §32.4 is the answer. A certificate typically reports purity by an unnamed HPLC method and sometimes a mass spectrum. Taken entirely at face value, that addresses identity and peptide purity — two items on a long list — and says nothing about sterility, endotoxin, content, stability, formulation, or chain of custody after testing. It is also, generally, a document supplied by the seller about a batch you cannot independently connect to the vial in your hand. Chapter 34 covers what independent testing can establish; the honest summary is more than nothing and considerably less than a quality system.

🩺 Safety and Risk — the specific things that are missing

It would be easy to read §32.9 as generalized disapproval. It is not. The value of the section is that the missing items are specific, and specific things can be reasoned about.

Sterility. A peptide powder is not sterile, and dissolving it does not make it sterile. Injected non-sterile material can cause local or systemic infection. This is the most concrete physical risk, and it is entirely independent of whether the peptide is what the label says.

Endotoxin. Bacterial cell-wall fragments cause fever, inflammation, and in quantity a serious systemic reaction. They are heat-stable and are not removed by anything a purity assay measures.

Content uncertainty. From §32.4: the labeled mass and the actual peptide mass are different numbers, and the gap is not small. Anyone reasoning quantitatively from a vial label is reasoning from a figure with unquantified error in a known direction.

Impurity profile. From §32.3: the impurities that matter are near-identical peptides, and their biological properties are unstudied by definition. "It's 99% pure" is a statement about the 99%. What the 1% is, and whether it is immunogenic, is addressed by nothing on a typical certificate.

Stability. No stability program means no basis for any statement about how the material behaves after storage, temperature excursion, or reconstitution.

And an absence of accountability. If something goes wrong there is no manufacturer with a regulatory obligation, no adverse-event reporting pathway, no recall mechanism, and — because these products are sold outside medical use — often no clinician who knows the exposure occurred.

Decisions here belong with a clinician who knows your history. What this chapter offers is not a decision but a vocabulary: you can now name what is present, what is absent, and what a given document does and does not establish.

📋 Your Evidence Dossier

Field 1 revisited — what "the same peptide" actually means.

Chapter 1 had you fill in Field 1, Identity, for each of your dossier compounds: name, other names, class, length, molecular weight, sequence availability. At the time, that looked like the easy field — the only one that seemed to have definite answers. This chapter complicates it, productively.

Two vials can carry identical labels — same name, same stated sequence, same stated mass, same stated purity — and contain materially different things. Not necessarily through fraud; through the ordinary operation of everything in §32.3 and §32.4. They may differ in:

• Impurity profile — which deletion sequences, and how much of each, depending on which couplings were difficult in that process
• Stereochemical purity — how much racemized material, depending on the activation chemistry used
• Counterion — trifluoroacetate, acetate, hydrochloride, or a mixture, and how much
• Water content — depending on drying, packaging, and handling
• Actual peptide mass — the labeled figure minus the two items above
• Salt form and buffer — for anything formulated rather than a bare powder
• Sterility and endotoxin status — which is not a property of the molecule at all, but is entirely a property of the preparation
• Stability history — what temperature it has seen, for how long

The identity of the molecule is a fixed fact. The identity of the preparation is not, and it is the preparation that gets used.

The task

For each compound in your dossier, extend Field 1 with a short block answering one question: what would I need to know to say that two preparations of this are the same?

FIELD 1+ — PREPARATION IDENTITY
  Route                    synthetic / recombinant / hybrid / unknown
  Why that route           length, non-natural residues, modification, folding
  Expected hard part       what §32.3–§32.6 predicts is difficult about making this
  Likely major impurity    what kind of thing the process tends to leave behind
  Purity claim available   yes / no — and BY WHAT METHOD, named
  Content claim available  yes / no — and by what method
  Counterion stated        yes / no — which
  Sterility / endotoxin    stated / not stated / not applicable
  Standard it is made to   named monograph and standard, or "none stated"
  What I still cannot say  the honest residue

Worked demonstration — two entries, deliberately opposite

FIELD 1+ — SEMAGLUTIDE (an approved product)     [worked demonstration]
  Route                 Hybrid. Backbone by chemical synthesis or a synthesis/
                        expression combination, plus defined chemical acylation.
  Why that route        Contains Aib at position 8 — not ribosomally encodable —
                        and a fatty diacid attached via a defined linker to one
                        specific lysine. Chemistry is mandatory (§32.6).
  Expected hard part    31 residues is demanding but industrial; the acylation
                        must be regioselective, which is why position 34 was
                        changed to arginine (§32.3).
  Likely major impurity Deletion sequences; incompletely or incorrectly acylated
                        species; process-related residues.
  Purity claim          Yes — to a defined specification, by validated methods,
                        on every batch, subject to inspection.
  Content claim         Yes — content is a specified, tested parameter.
  Counterion            Defined by the formulation, which is itself specified.
  Sterility/endotoxin   Specified and tested; aseptically filled (§32.7).
  Standard              A regulatory dossier and, where applicable, a
                        pharmacopeial standard. Named, public, enforced.
  Still cannot say      Nothing important about identity or composition. The open
                        questions about this molecule are clinical, not chemical.

FIELD 1+ — A RESEARCH-CHEMICAL PEPTIDE           [worked demonstration]
  Route                 Almost certainly solid-phase synthesis (§32.1).
  Why that route        Short enough that synthesis is the obvious route; no
                        folding requirement that would demand a cell.
  Expected hard part    Depends on sequence. Runs of certain residues can cause
                        on-resin aggregation and drive down per-step efficiency
                        (§32.2), which drives up deletion content (§32.3).
  Likely major impurity Deletion sequences differing by one residue — the hardest
                        class to detect and to remove.
  Purity claim          Usually stated as a number. Usually WITHOUT the method,
                        the column, the gradient, or evidence that the method
                        resolves this process's impurities. Uninterpretable
                        as stated (§32.4).
  Content claim         Almost never stated. The labeled mass is what was
                        weighed, not what is peptide.
  Counterion            Usually not stated. Frequently trifluoroacetate.
  Sterility/endotoxin   Not stated and not applicable — the product is sold as
                        a non-pharmaceutical.
  Standard              None stated. "Pharmaceutical grade" is not a standard
                        (§32.4).
  Still cannot say      Whether two vials with the same label are the same
                        material; how much peptide is present; what the
                        impurities are; whether it is sterile; how it has
                        been stored.

Notice what has happened to Field 1. In Chapter 1, the difference between an approved drug and a research chemical showed up as a naming fact: one had a generic name from an international authority, the other had a laboratory code. That was a real signal, and it was visible before any evidence was consulted.

Field 1+ shows the same divide from the manufacturing side, and it is sharper. The difference is not that one product is good and the other is bad. The difference is that for one of them, the question "are these two vials the same?" has a defined, documented, enforceable answer, and for the other it does not have an answer at all.

Finally, a note for your own record. Date this entry. Manufacturing changes. Processes are improved, suppliers change, standards are revised, and products move between routes. A statement about how something is made is a statement about a moment, and Chapter 40 will ask you to look back at what you wrote and see which parts aged.

Conclusion

Peptide manufacturing runs on two routes and one piece of arithmetic.

The first route is chemical. Merrifield's 1963 insight — anchor the growing chain to something insoluble so that everything else can be washed away — converted peptide synthesis from a research career into a cycle a machine can repeat, and essentially every molecule in this book, prescription and gray market alike, descends from it. The cycle is a discipline of protecting groups: cap everything, uncap exactly one thing, do exactly one reaction, wash, repeat.

The arithmetic is the constraint that shapes everything else. At 99% efficiency per coupling, a 10-residue peptide comes out around 90% correct, a 30-residue peptide around 74%, a 50-residue peptide around 61%. What did not make it is not absent — it is deletion sequences, chains missing one residue out of thirty, chemically and chromatographically almost indistinguishable from the product. That is why long peptides are made in cells rather than flasks, why cosmetic peptides are short, why a purity number needs a named method behind it to mean anything, and why a company would change a residue in a drug molecule purely to eliminate an ambiguity in a manufacturing step.

The second route is biological. Insert a gene, grow the organism, harvest the product — and discover, as the insulin developers did before 1982, that expression was the tractable half and folding was the hard half. Six cysteines, fifteen possible pairings, one correct answer, and no guarantee from the sequence alone. Nature's own solution was a linker whose only job was to make folding easy and then leave, and industry eventually adopted it.

Then everything after the molecule exists, which is most of the cost and nearly all of the constraint: formulation, sterile filling, devices, cold chain, testing. The GLP-1 shortage this book has referred to since Part II was never a synthesis problem. It was a fill-finish and device-assembly problem, and it persisted through the largest commercial incentive in the industry because a validated sterile line takes years to build and money does not shorten years by much.

Which brings the sentence worth carrying out of this chapter. A research vial is cheaper than a prescription because it is a different product, not because someone found efficiencies. Formulation, sterile fill-finish, device, cold chain, quality system, regulatory compliance, clinical evidence, and accountability are each absent, each cost real money, and each exist so that someone does not have to hope.

Chapter 33 turns to the other half of Part VI: not how peptides are made, but how they are designed — the engineering toolkit that turns a fragile natural hormone into a molecule that survives a week in the bloodstream. You have already met several of its tools in this chapter without being told that is what they were.

Key Terms

Solid-phase peptide synthesis (SPPS) — Merrifield's 1963 method, in which a peptide chain is assembled while anchored to an insoluble support so that excess reagents and byproducts can be washed away after each step rather than separated chromatographically.

Resin (solid support) — the insoluble polymer beads the growing chain is anchored to. Typically swellable, so chemistry occurs throughout a porous interior rather than only on an outer surface.

Linker — the connector between resin and peptide, chosen to hold through every cycle and release cleanly under defined conditions at the end.

Protecting group — a chemical cap that renders a reactive group temporarily inert, removable later under conditions that leave everything else intact.

Fmoc — the base-removable N-terminal protecting group of the dominant modern strategy, paired with acid-removable side-chain groups so the two respond to different triggers. Boc is the acid-removable N-terminal group of Merrifield's original strategy.

Deprotection — removal of a protecting group; each cycle removes the N-terminal cap to expose exactly one reactive amino group.

Coupling — the bond-forming step joining the next protected amino acid, made reactive by an activating reagent, to the free N-terminus of the growing chain.

Racemization — inversion of a residue's configuration during activation, producing a mirror-image residue: identical mass, different molecule.

Capping — permanently blocking chains that failed a coupling, converting deletion sequences into truncated sequences, which are easier to separate. It does not improve yield.

Cleavage — the final step releasing the chain from the resin, generally removing side-chain protecting groups at the same time.

Deletion sequence — a chain missing one or more internal residues because a coupling failed and the chain kept growing. The characteristic impurity of peptide synthesis, and unusually hard to remove because it is nearly identical to the product. A truncated sequence stopped growing altogether, and is easier to separate because it differs more.

Preparative HPLC — liquid chromatography run at a scale intended to collect purified material rather than measure it. The standard purification method for synthetic peptides.

Purity by peak area — the product peak's integrated area as a percentage of total integrated peak area. A ratio among detected species, not a statement about mass, identity, or anything undetected.

Peptide content — the fraction of a preparation's total mass that is actually peptide. A different quantity from purity, determined by different methods.

Counterion — the ion paired with a charged group on the peptide. Trifluoroacetate is common because trifluoroacetic acid is used in cleavage and in HPLC, and it contributes real mass.

Lyophilization — freeze-drying; the usual final isolation step, producing a hygroscopic powder that retains residual water.

Recombinant DNA production — inserting the gene for a peptide into a host organism (the expression system, commonly E. coli, yeast, or a mammalian cell line), growing it, and harvesting the product.

Inclusion body — a dense intracellular aggregate of misfolded protein formed when a host overexpresses a foreign protein; recoverable, but requiring refolding into the correct three-dimensional structure with correct disulfide pairing.

Proinsulin — insulin's single-chain precursor, in which a connecting segment holds the future A and B chains together so folding brings the correct cysteines together. The segment is removed enzymatically after folding.

Fragment condensation — building a long peptide from separately synthesized and purified pieces, avoiding the yield collapse of many sequential couplings.

Aseptic fill-finish — dispensing a sterile solution into sterile containers in a controlled environment, used when the product cannot be sterilized in its final container.

Endotoxin — bacterial cell-wall material causing fever and inflammation when injected. Not detected or removed by chemical purity methods; controlled by a separate test.

GMP (Good Manufacturing Practice) — the enforceable framework governing pharmaceutical manufacture: facilities, processes, documentation, testing, and release.

Pharmacopeial monograph — a published public standard for a specific substance listing required tests, methods, and limits. Naming one makes a quality claim specific and checkable.

Certificate of analysis — a document reporting a batch's test results. Its value depends entirely on which tests, by what methods, by whom, and whether the batch connects to the material in hand.

Spaced Review

1. A process couples at 99% per step. Calculate the theoretical yield of correct full-length product for a 15-residue peptide and for a 45-residue peptide. Then explain, using Chapter 1 §1.5, why the peptide/protein size convention has an accidental relationship to this arithmetic — and say explicitly why the relationship is accidental rather than causal.

2. Chapter 4 explained that semaglutide's Aib at position 8 blocks DPP-4 cleavage, and that the position-34 arginine substitution prevents a mixture of attachment isomers. For each of those two modifications, state whether it is primarily a pharmacological design choice or primarily a manufacturing design choice, and defend your answer. What does the pair tell you about how analogs are actually designed?

3. Chapter 19 described a market in which products of uncertain composition are sold for human use. Using §32.3 and §32.4, name the two most likely specific sources of that uncertainty for a competently synthesized 20-residue peptide — and explain why neither would be revealed by a certificate reporting only "99% purity by HPLC."

4. A friend shows you two products. One is a prescription pen; the other is a vial from a website, at a small fraction of the price, with a certificate of analysis attached. Using §32.8 and §32.9, list five specific things the price difference is paying for that are not the molecule. Then, using §32.4, state what the certificate does establish, so that your answer is fair rather than merely dismissive.

5. Growth hormone is 191 residues and is produced recombinantly; oxytocin is 9 residues and is produced synthetically. Using Chapter 1's size spectrum together with §32.3 and §32.6, explain the division — and then identify the one factor that could force a short peptide to be made recombinantly, or a long one to require chemical steps.